Detailed Information on Publication Record
2023
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
ILARIA, Del Principe Maria, Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL et. al.Basic information
Original name
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
Authors
ILARIA, Del Principe Maria (guarantor), Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Monica PIEDIMONTE, Francesco MARCHESI, Gianpaolo NADALI, Philipp KOEHLER, Nicola FRACCHIOLLA, Chiara CATTANEO, Nikolai KLIMKO, Angelica SPOLZINO, Deniz Yilmaz KARAPINAR, Hayati DEMIRASLAN, Rafael F DUARTE, Judit DEMETER, Marta STANZANI, Lorella Maria Antonia MELILLO, Claudia Maria BASILICO, Simone CESARO, Giovangiacinto PATERNO, Catello CALIFANO, Mario DELIA, Elisa BUZZATTI, Alessandro BUSCA, Oliver A CORNELY, Livio PAGANO, Nael ALAKEL, Valentina Arsi ARSENIJEVI'C, Vincent CAMUS, Iker FALCES-ROMERO, Levy ITZHAK, Michal KOUBA (203 Czech Republic), Rodrigo MARTINO, Petr SEDLACEK (203 Czech Republic) and Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution)
Edition
Mycoses, Hoboken, Wiley-Blackwell, 2023, 0933-7407
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.900 in 2022
RIV identification code
RIV/00216224:14110/23:00130241
Organization unit
Faculty of Medicine
UT WoS
000855011600001
Keywords in English
antifungal treatment; Candidemia; fungal infection; Geotrichum; Magnusiomyces; Saprochaete
Tags
International impact, Reviewed
Změněno: 4/10/2024 08:54, Mgr. Tereza Miškechová
Abstract
V originále
Background Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2-78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p < .0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p = .001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396-5.204, p = .003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151-4.376, p = .018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102-7.601, p < .001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192-5.222, p = .015). Conclusions Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.